278 related articles for article (PubMed ID: 19036086)
1. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.
Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA
Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
Song D; Chaerkady R; Tan AC; García-García E; Nalli A; Suárez-Gauthier A; López-Ríos F; Zhang XF; Solomon A; Tong J; Read M; Fritz C; Jimeno A; Pandey A; Hidalgo M
Mol Cancer Ther; 2008 Oct; 7(10):3275-84. PubMed ID: 18852131
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
5. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
6. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis.
Redlak MJ; Miller TA
Dig Dis Sci; 2011 Feb; 56(2):323-9. PubMed ID: 20585984
[TBL] [Abstract][Full Text] [Related]
9. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Powers MV; Clarke PA; Workman P
Cancer Cell; 2008 Sep; 14(3):250-62. PubMed ID: 18772114
[TBL] [Abstract][Full Text] [Related]
12. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.
Cohen SM; Mukerji R; Samadi AK; Zhang X; Zhao H; Blagg BS; Cohen MS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S483-90. PubMed ID: 21837531
[TBL] [Abstract][Full Text] [Related]
13. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
[TBL] [Abstract][Full Text] [Related]
15. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Dewaele B; Wasag B; Cools J; Sciot R; Prenen H; Vandenberghe P; Wozniak A; Schöffski P; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2008 Sep; 14(18):5749-58. PubMed ID: 18794084
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
17. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibitor enhances apoptosis by inhibiting the AKT pathway in thermal-stimulated SK-MEL-2 human melanoma cell line.
Shin MK; Jeong KH; Choi H; Ahn HJ; Lee MH
J Dermatol Sci; 2018 Jun; 90(3):357-360. PubMed ID: 29433909
[TBL] [Abstract][Full Text] [Related]
19. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
Douglas M; Lim AR; Porter JR; West K; Pink MM; Ge J; Wylie AA; Tibbits TT; Biggs K; Curtis M; Palombella VJ; Adams J; Fritz CC; Normant E
Mol Cancer Ther; 2009 Dec; 8(12):3369-78. PubMed ID: 19952119
[TBL] [Abstract][Full Text] [Related]
20. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
